Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710318 | 0.96 | PKM (0.43) | KMT2APKMMEN1GAAEPHX2 | |
| SCHEMBL2394793 | 0.86 | TGM2 (0.44) | KMT2AMEN1GAAEPHX2 | |
| SCHEMBL2391300 | 0.81 | TGM2 (0.45) | KMT2APKMMEN1EPHX2MAPT | |
| SCHEMBL5447251 | 0.78 | ALDH1A1 (0.52) | KMT2APKMMEN1GAAF10 | |
| SCHEMBL2394467 | 0.77 | EPHX2 (0.49) | KMT2AMEN1EPHX2ALDH1A1LMNA | |
| SCHEMBL5436955 | 0.77 | SMN1; SMN2 (0.52) | PKMGAAEPHX2POLBLMNA | |
| SCHEMBL2394987 | 0.76 | LMNA (0.34) | KMT2APKMMEN1EPHX2LMNA | |
| SCHEMBL2392198 | 0.76 | EPHX2 (0.41) | EPHX2ALDH1A1LMNAMAPT | |
| SCHEMBL2392201 | 0.76 | LMNA (0.41) | GAAEPHX2LMNA | |
| SCHEMBL2395625 | 0.75 | ALDH1A1 (0.40) | KMT2APKMMEN1GAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012980-B2 | Isoquinolinone derivatives | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| EP-2344472-A1 | ISOQUINOLINONE DERIVATIVES | AstraZeneca AB (SE) | 2011-07-20 | — | — | EP | disclosed |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010039079-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | SDHA, NQO1, CYP3A5 | KMT2A 2104/4885PKM 1010/4885MEN1 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.